Moomoo AI 已提取核心訊息
Illumina, Inc., a leading company in the genomics industry, filed a Form 8-K with the U.S. Securities and Exchange Commission on January 4, 2024. The report announced the departure of Susan Tousi, the Chief Commercial Officer of Illumina, effective January 5, 2024. Following Tousi's departure, Bas Verhoef, currently Head of Region – Europe, will assume the role of Interim Chief Commercial Officer. The company's common stock is registered under the trading symbol ILMN on the NASDAQ. This executive change comes as part of the company's ongoing management adjustments and has been officially documented in the report signed by Charles E. Dadswell, General Counsel and Secretary of Illumina, Inc.
Illumina, Inc., a leading company in the genomics industry, filed a Form 8-K with the U.S. Securities and Exchange Commission on January 4, 2024. The report announced the departure of Susan Tousi, the Chief Commercial Officer of Illumina, effective January 5, 2024. Following Tousi's departure, Bas Verhoef, currently Head of Region – Europe, will assume the role of Interim Chief Commercial Officer. The company's common stock is registered under the trading symbol ILMN on the NASDAQ. This executive change comes as part of the company's ongoing management adjustments and has been officially documented in the report signed by Charles E. Dadswell, General Counsel and Secretary of Illumina, Inc.
基因組學行業的領先公司Illumina, Inc. 於2024年1月4日向美國證券交易委員會提交了8-K表格。該報告宣佈，Illumina首席商務官蘇珊·圖西自2024年1月5日起離職。圖西離職後，現任歐洲地區負責人Bas Verhoef將擔任臨時首席商務官一職。該公司的普通股在納斯達克註冊的交易代碼爲ILMN。此次高管變動是公司正在進行的管理調整的一部分，並已正式記錄在Illumina, Inc.總法律顧問兼秘書查爾斯·達德斯韋爾簽署的報告中。
基因組學行業的領先公司Illumina, Inc. 於2024年1月4日向美國證券交易委員會提交了8-K表格。該報告宣佈，Illumina首席商務官蘇珊·圖西自2024年1月5日起離職。圖西離職後，現任歐洲地區負責人Bas Verhoef將擔任臨時首席商務官一職。該公司的普通股在納斯達克註冊的交易代碼爲ILMN。此次高管變動是公司正在進行的管理調整的一部分，並已正式記錄在Illumina, Inc.總法律顧問兼秘書查爾斯·達德斯韋爾簽署的報告中。
有用
沒用